GlassScriptPhysician profile
Traci Jo Parillo
NPI 1457968307
$1,605.93
in general payments reported to CMS, 2019-2025
16 companies · $855 in 2025
The $855 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $323 · 2024: $428 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.93 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $459.56 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $276.77 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $211.25 | 2023-2025 | |
| Axsome Therapeutics, INC. | $173.34 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $65.84 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $65.52 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $63.68 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.31 | 2023 | Trulance, Xifaxan |
| Ardelyx, INC. | $40.28 | 2025 | Ibsrela |
| Pfizer INC. | $38.24 | 2025 | |
| Abbott Laboratories | $37.16 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $33.61 | 2023 | Quviviq |
| Amgen INC. | $30.09 | 2024-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.64 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $20.40 | 2023 | Injectafer |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Parillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.